Kottil Rammohan, MD: The new MS drug Gilenya (fingolimod)
Interviewed by Steven Greer, MD
Kottil Rammohan, MD, Director of the Multiple Sclerosis Division of Neurology at the University of Miami Miller School of Medicine, discusses the newly approved drug for first-line therapy of MS branded as Gilenya (fingolimod). He addresses the efficacy of the drug and whether the cost of more than $40,000 per year will limit the usage to second-line therapy.
Multiple Sclerosis, Neurology, Univ Miami | apples49 | 
March 13, 2012 11:09 am
No Comments
No comments yet.
Notice: comments_rss_link is deprecated since version 2.5! Use post_comments_feed_link() instead. in /data/30/1/121/80/1121895/user/1185656/htdocs/wordpress/wp-includes/functions.php on line 3406
RSS feed for comments on this post.
TrackBack URI
